


# All cancer sites


Average chemotherapy use



## Australia

New South Wales

\*Victoria



## Canada

Ontario

Alberta


British Columbia

\*Manitoba

\*Prince Edward Island


Nova Scotia

\*Saskatchewan



## Norway

\*Norway




## UK

England

\*Wales

Scotland

Northern Ireland



'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (\*).

Chemotherapy use may be underestimated in Manitoba, Norway, Victoria, and Wales for colon, rectal, and liver cancer due to undercounting oral chemotherapy when used as a single treatment.


Jurisdictions with incomplete data were excluded.

# Oesophageal cancer


Average chemotherapy use vs 1- and 5- year net survival




## Australia




## Canada



## Norway



## UK



Average chemotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.  
 'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis.  
 Jurisdictions with incomplete data or less than 100 patients were excluded.


# Colon cancer




## Average chemotherapy use vs 1- and 5- year net survival




### Australia




### Canada



### Norway



### UK



Average chemotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.

'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (\*).


Chemotherapy use may be underestimated in Manitoba, Norway, Victoria, and Wales for colon cancer due to undercounting oral chemotherapy when used as a single treatment. Jurisdictions with incomplete data were excluded.

# Colon stage III cancer


Average chemotherapy use vs 1- and 5- year net survival




## Australia



## Canada



## UK



Average chemotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.

Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (\*).


Chemotherapy use may be underestimated in Manitoba, Victoria, and Wales for colon cancer due to undercounting oral chemotherapy when used as a single treatment. Jurisdictions with incomplete data were excluded.

# Stomach cancer


## Average chemotherapy use vs 1- and 5- year net survival




### Australia




### Canada



### Norway



### UK



Average chemotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.  
 'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis.  
 Jurisdictions with incomplete data or less than 100 patients were excluded.


# Rectal cancer




## Average chemotherapy use vs 1- and 5- year net survival




### Australia




### Canada



### Norway



### UK



Average chemotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.

'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (\*).

Chemotherapy use may be underestimated in Manitoba, Norway, Victoria, and Wales for rectal cancer due to undercounting oral chemotherapy when used as a single treatment. Jurisdictions with incomplete data were excluded.

# Liver cancer


## Average chemotherapy use



### Australia

New South Wales

\*Victoria



### Canada

Alberta


Ontario

British Columbia

\*Manitoba

Saskatchewan

Nova Scotia



### Norway

\*Norway




### UK

England

Scotland

\*Wales

Northern Ireland



'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (\*).


Chemotherapy use may be underestimated in Manitoba, Norway, Victoria, and Wales for liver cancer due to undercounting oral chemotherapy when used as a single treatment. Jurisdictions with incomplete data were excluded.

# Pancreatic cancer


Average chemotherapy use vs 1- and 5- year net survival




## Australia




## Canada



## Norway



## UK




Average chemotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.  
 'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis.  
 Jurisdictions with incomplete data were excluded.

# Lung cancer


## Average chemotherapy use vs 1- and 5- year net survival




### Australia




### Canada



### Norway



### UK




Average chemotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.  
 'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis.  
 Jurisdictions with incomplete data were excluded.

# Ovarian cancer


Average chemotherapy use vs 1- and 5- year net survival




## Australia




## Canada



## Norway



## UK



Average chemotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.  
 'Overall average use' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (\*).  
 Jurisdictions with incomplete data were excluded.